CryoPort, Inc. (NASDAQ:CYRX) is set to issue its quarterly earnings data after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.

CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, August 8th. The company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.01. The company had revenue of $2.92 million during the quarter, compared to the consensus estimate of $2.84 million. CryoPort had a negative return on equity of 67.75% and a negative net margin of 102.89%. On average, analysts expect CryoPort to post $-0.31 EPS for the current fiscal year and $-0.23 EPS for the next fiscal year.

CryoPort, Inc. (NASDAQ CYRX) traded up 2.1995% during mid-day trading on Tuesday, reaching $7.7876. The company had a trading volume of 81,540 shares. The company’s market capitalization is $192.15 million. The firm has a 50-day moving average of $8.77 and a 200 day moving average of $5.95. CryoPort, Inc. has a 1-year low of $1.96 and a 1-year high of $10.40.

Several research firms have recently issued reports on CYRX. Janney Montgomery Scott set a $8.00 price objective on CryoPort and gave the company a “buy” rating in a research note on Wednesday, July 26th. Needham & Company LLC raised their price target on CryoPort from $6.00 to $8.50 and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Finally, Cowen and Company raised their price target on CryoPort from $5.50 to $7.50 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th.

A hedge fund recently raised its stake in CryoPort stock. Northern Trust Corp increased its holdings in shares of CryoPort, Inc. (NASDAQ:CYRX) by 105.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 22,179 shares of the company’s stock after acquiring an additional 11,358 shares during the period. Northern Trust Corp owned about 0.09% of CryoPort worth $109,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at

About CryoPort

Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.

Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.